4 reasons why now is the perfect time to invest in the Medical Cannabis Market
With recent reforms happening in Australia allowing the use of Medical Cannabis for medicinal purposes, there is widespread excitement and enthusiasm for investment in the Medical Cannabis market.
With companies regularly entering the Medical Cannabis industry in Australia, it would be fair to wonder why there is so much interest in the market, and whether or not to invest.
Here are 4 reasons why you should look into investing in the Medical Cannabis market:
1. The research speaks for itself
The medical and wider community are just beginning to understand what Medical Cannabis can do. New research is being undertaken, to prove the benefits of Medical Cannabis. Early findings have suggested that it can effectively treat chronic pain, chemotherapy induced nausea, symptoms of multiple sclerosis (MS), epilepsy and post-traumatic stress disorder (PTSD).
MGC Pharmaceuticals has also just begun ground-breaking new research, collaborating with RMIT University to uncover how Medical Cannabis can treat Melanoma cancer.
While the world is still in the early stages of understanding what Medical Cannabis can do, the early results are overwhelmingly positive. We believe this will lead to increased demand for an already booming market.
2. Sales of Medical Cannabis are on the rise
Recent research into Medical Cannabis sales by Marijuana investment group, Arcview, showed that last year Medical Cannabis sales hit $US6.7 billion in the United States alone. That equates to roughly $8.25 billion AUD. The report also predicted that this number will grow to $US21 billion by 2021 (roughly $26 billion AUD). We hope to see this trend continue to rise.
3. Big market potential
There’s a significant market valued at $200 million AUD in Australia. A white paper developed by MGC Pharma and the University of Sydney found that there would be a patient portfolio of around 30,000 Australians with HIV, epilepsy and MS that would seek to use Medical Cannabis for treatment in the future.
4. You’re part of a movement
There’s been a negative stigma surrounding Medical Cannabis for decades. Fortunately there were people that recognised the benefits and how it can effectively treat children who suffer from severe epilepsy, people with chronic pain and many other diseases. Now that the effects of Medical Cannabis have been recognised by a wider community and it has been legalised in countries across the world, it’s the perfect time to join the movement and help improve the lives of patients around the world.
Did you know?
MGC Pharmaceuticals Ltd (ASX: MXC) is a global specialist Medical Grade Cannabis company with many years of technical, clinical and commercial experience in the industry. The Company’s founders are all key figures in the Israeli Medical Cannabis industry. MGC Pharma’s core business strategy is to develop and supply high quality Cannabinoid based pharmaceutical products for the growing Medical markets in Europe, North America and Australasia.
We have a diverse range of leaders at MGC Pharmaceuticals, all with a wealth of experience and a dedication to health and bringing Medical Cannabis to the forefront of Medical research and innovation.
We believe that Medical Cannabis will effectively treat previously unmet medical needs and improve the lives of patients, impacting public health across the world.
MGC embraces this by creating pharmaceutical grade products and providing them in various markets. These products are registered for sale and leverage the Company’s own proprietary Medical Cannabis formula through clinical trials in Europe, Israel and Australia. In addition, tertiary and supplementary revenue streams solidify our presence in the market.
This enables future Medical product sales across the European Union, Australia and other geographies, following the requisite legal and regulatory approvals.
